Search

Gossamer Bio Inc

Fechado

SetorSaúde

0.18 20

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.15

Máximo

0.16

Indicadores-chave

By Trading Economics

Rendimento

64M

17M

Vendas

-7.7M

9.2M

EPS

-0.2

Margem de lucro

182.94

Funcionários

161

EBITDA

-28M

-71M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+613.33% upside

Dividendos

By Acuity

Próximos Ganhos

3 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-18M

68M

Abertura anterior

-19.82

Fecho anterior

0.18

Sentimento de Notícias

By Acuity

76%

24%

318 / 340 Ranking em Healthcare

Gossamer Bio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de ago. de 2026, 00:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market gains despite no specific company news identified.

21 de ago. de 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following broader market gains despite earlier lower trading. No specific news was identified for the move.

20 de ago. de 2026, 23:01 UTC

Gossamer Bio shares are lower in after-market trading, reflecting broader market pressures following Walmart's disappointing sales growth and guidance.

19 de ago. de 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following a notable peak earlier in the session. The stock remains below its 20-day moving average.

18 de ago. de 2026, 23:01 UTC

Gossamer Bio Inc shares rose in after-market trading following Tuesday's close, though no specific news was identified to explain the movement.

17 de ago. de 2026, 23:31 UTC

Gossamer Bio Inc shares are sharply higher in after-market trading, rising significantly despite being below its 20-day moving average and recent declines.

15 de ago. de 2026, 00:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, though no specific news explains the movement. The price remains below its 20-day moving average.

14 de ago. de 2026, 22:51 UTC

Gossamer Bio Inc. shares are higher in after-market hours, despite disappointing U.S. retail sales data influencing broader market sentiment.

13 de ago. de 2026, 23:01 UTC

News

Gossamer Bio reported second-quarter net income of $16.9 million and plans to submit a New Drug Application for seralutinib in September 2026. Shares are higher in after-market trading.

12 de ago. de 2026, 23:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, continuing a strong performance since July 13, despite earlier fluctuations during the session.

11 de ago. de 2026, 23:11 UTC

No specific news was identified for Gossamer Bio Inc. in after-market trading, with shares effectively unchanged since Tuesday's close.

10 de ago. de 2026, 23:01 UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting strong performance and positioning above the 20-day moving average. No specific news was identified.

7 de ago. de 2026, 19:56 UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

6 de ago. de 2026, 23:12 UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

5 de ago. de 2026, 23:36 UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

4 de ago. de 2026, 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

3 de ago. de 2026, 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1 de ago. de 2026, 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31 de jul. de 2026, 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30 de jul. de 2026, 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29 de jul. de 2026, 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28 de jul. de 2026, 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27 de jul. de 2026, 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24 de jul. de 2026, 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23 de jul. de 2026, 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22 de jul. de 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20 de jul. de 2026, 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Comparação entre Pares

Variação de preço

Gossamer Bio Inc Previsão

Preço-alvo

By TipRanks

613.33% parte superior

Previsão para 12 meses

Média 1.07 USD  613.33%

Máximo 2 USD

Mínimo 0.28 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Gossamer Bio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

2

Comprar

2

Manter

1

Vender

Sentimento

By Acuity

318 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
help-icon Live chat